Proteolysis & Peptides

Proteolysis is the hydrolysis of peptide bonds by enzymes called proteases (or peptidases). It is one of the most fundamental processes in biology — governing protein turnover, signal termination, immune defense, and the generation of bioactive peptide fragments. For peptide therapeutics, proteolysis is also the central challenge: the same enzymatic machinery that degrades endogenous signaling peptides on cue will degrade exogenous peptide drugs before they reach their targets.

Major proteolytic pathways

The ubiquitin-proteasome system

The ubiquitin-proteasome system (UPS) is the primary pathway for targeted intracellular protein degradation. It handles 80-90% of intracellular protein turnover and is highly selective.

Mechanism:

1. Ubiquitin tagging: A cascade of enzymes (E1 activating, E2 conjugating, E3 ligase) attaches polyubiquitin chains to lysine residues on the target protein. The E3 ligase determines substrate specificity — the human genome encodes over 600 E3 ligases.
2. Proteasomal recognition: The 26S proteasome recognizes K48-linked polyubiquitin chains (four or more ubiquitin molecules).
3. Unfolding and degradation: The 19S regulatory cap unfolds the protein and threads it into the 20S core, a barrel-shaped structure containing threonine protease active sites. The protein is cleaved into peptide fragments of 3-25 amino acids.
4. Peptide release: These fragments are further degraded by cytosolic aminopeptidases — or, in some cases, loaded onto MHC class I molecules for immune presentation.

The UPS is critical for cell cycle regulation, transcription factor turnover, and quality control of misfolded proteins. Proteasome inhibitors (bortezomib, carfilzomib) are used in cancer therapy precisely because they block this degradation pathway.

Lysosomal and autophagic proteolysis

Lysosomes are acidic organelles (pH 4.5-5.0) containing a battery of proteases called cathepsins. They degrade proteins delivered via three routes:

• Endocytosis: Extracellular proteins internalized by receptor-mediated or fluid-phase endocytosis
• Phagocytosis: Pathogens or debris engulfed by macrophages and neutrophils
• Autophagy: Cytoplasmic contents sequestered in autophagosomes and delivered to lysosomes for bulk degradation

Cathepsins (B, D, L, S, and others) are endopeptidases and exopeptidases that operate optimally at acidic pH. They are particularly relevant to peptide science because cathepsin-mediated degradation in endosomes limits the intracellular delivery of peptide drugs internalized via receptor-mediated endocytosis.

Calpain system

Calpains are calcium-dependent cysteine proteases that perform limited proteolysis — they cleave specific sites in target proteins rather than degrading them completely. This limited cleavage often activates or modulates protein function rather than eliminating it.

Calpain-1 (micro-calpain) and calpain-2 (milli-calpain) are ubiquitously expressed and regulate cytoskeletal remodeling, signal transduction, and membrane repair. Dysregulated calpain activity contributes to neurodegeneration, muscular dystrophy, and ischemia-reperfusion injury.

Extracellular proteases

The extracellular environment contains its own proteolytic machinery:

• Matrix metalloproteinases (MMPs): Zinc-dependent endopeptidases that degrade extracellular matrix proteins (collagen, elastin, fibronectin). MMP activity is central to wound remodeling, angiogenesis, and tumor invasion.
• Serine proteases: Trypsin, chymotrypsin, elastase, and thrombin are serine proteases that operate in digestion, coagulation, and complement activation.
• Dipeptidyl peptidase IV (DPP-IV): A serine exopeptidase that cleaves N-terminal dipeptides from substrates with proline or alanine at position 2. DPP-IV rapidly inactivates GLP-1 and GIP (incretin hormones), giving them half-lives under 2 minutes. DPP-IV inhibitors (sitagliptin, saxagliptin) are approved diabetes drugs.

Proteolysis as a source of bioactive peptides

Proteolysis is not only degradative — it generates biologically active peptide fragments with distinct functions from their parent proteins:

Matrikines

When extracellular matrix proteins (collagen, fibronectin, elastin) are degraded by MMPs or other proteases, the resulting fragments — called matrikines — act as signaling molecules. GHK (glycyl-histidyl-lysine) is a tripeptide released from collagen degradation that signals fibroblasts to synthesize new collagen. This feedback loop links proteolysis directly to tissue repair.

Cryptides

Many proteins contain encrypted bioactive peptide sequences that are released only upon proteolytic cleavage. Hemoglobin, for example, yields hemorphins (opioid-like peptides) and hemocidins (antimicrobial peptides) when cleaved. Lactoferrin yields lactoferricin, an antimicrobial peptide, upon gastric digestion. These cryptides expand the functional repertoire of the proteome beyond what intact proteins can accomplish.

Antigen processing

Intracellular proteolysis by the proteasome generates the peptide fragments (8-10 amino acids) presented on MHC class I molecules. This process is the foundation of adaptive cellular immunity — cytotoxic T cells recognize infected or transformed cells based on the peptide fragments displayed on their surface.

Peptide stability against proteolytic degradation

The short half-life of most natural peptides (minutes in plasma) is the central pharmacokinetic challenge in peptide drug development. Several strategies have been developed to resist proteolysis:

D-amino acid substitution

Natural proteases evolved to recognize and cleave L-amino acid substrates. Substituting one or more L-amino acids with their D-enantiomers at protease-sensitive positions renders the peptide bond resistant to enzymatic cleavage. FOXO4-DRI, a retro-inverso peptide composed entirely of D-amino acids in reversed sequence, exploits this principle to achieve dramatically extended half-life while maintaining binding activity.

Cyclization

Cyclizing a peptide — connecting the N- and C-termini or side chains via amide, disulfide, or thioether bonds — constrains the molecule into a rigid structure that resists exopeptidase attack and reduces the conformational flexibility required for endopeptidase recognition. Cyclosporine A, a cyclic undecapeptide, has an oral bioavailability of ~30%, extraordinary for a peptide, largely because cyclization protects it from gastrointestinal proteases.

PEGylation

Conjugating polyethylene glycol (PEG) chains to a peptide creates a hydrophilic shield that sterically hinders protease access to cleavable bonds. PEGylation also increases hydrodynamic radius, reducing renal clearance. Pegylated BPC-157 represents an application of this strategy to extend the biological activity window of a naturally short-lived peptide.

N-methylation and backbone modifications

Methylating the amide nitrogen of the peptide backbone blocks hydrogen bonding required for protease-substrate recognition. This approach is used in several oral peptide drugs. Non-natural backbone elements — beta-amino acids, peptoids (N-substituted glycines), or azapeptides — similarly evade protease recognition while potentially retaining bioactivity.

Protease inhibitor co-administration

Rather than modifying the peptide itself, protease inhibitors can be co-administered to protect the intact peptide from degradation. Oral semaglutide (Rybelsus) uses this approach: it is co-formulated with the absorption enhancer SNAC, which also locally inhibits pepsin in the stomach.

Peptides that modulate proteolytic pathways

BPC-157

BPC-157 (Body Protection Compound-157) is a pentadecapeptide with remarkable resistance to gastrointestinal proteolysis — it retains biological activity when administered orally, an unusual property for a 15-amino-acid peptide. This stability likely results from its compact secondary structure and resistance to common GI proteases (pepsin, trypsin, chymotrypsin), though the precise structural features conferring this protection are not fully characterized. At wound sites, BPC-157 modulates MMP activity and growth factor receptor expression, influencing extracellular matrix turnover through indirect regulation of proteolytic balance.

Pegylated BPC-157

Pegylated BPC-157 demonstrates the PEGylation protection strategy applied to a specific therapeutic peptide. The polyethylene glycol conjugation extends the circulating half-life by shielding protease-sensitive sites while maintaining the peptide's wound-healing bioactivity. This represents the practical translation of proteolytic resistance engineering into an improved therapeutic product.

Proteasome-targeting peptides

Synthetic peptides that recruit E3 ubiquitin ligases to specific target proteins (PROTACs and molecular glues) represent a new therapeutic paradigm — using the cell's own proteolytic machinery to degrade disease-causing proteins. While most current PROTACs are small molecules, peptide-based degrons are in active development for targets inaccessible to small molecules.

Protease mapping for peptide drug design

Rational peptide drug design increasingly relies on protease mapping — identifying which specific proteases a candidate peptide is most vulnerable to, and where cleavage occurs in the sequence. Techniques include:

• In vitro protease incubation: Exposing the peptide to individual proteases (trypsin, chymotrypsin, DPP-IV, neprilysin) and analyzing fragments by mass spectrometry to identify cleavage sites
• Plasma stability assays: Incubating the peptide in human plasma and measuring intact peptide concentration over time — a composite readout of all plasma protease activity
• Protease-resistant analog screening: Systematically substituting amino acids at identified cleavage sites with D-amino acids, N-methylated residues, or non-natural amino acids, then re-testing stability

This approach has been applied successfully to GLP-1 analogs: native GLP-1 is rapidly cleaved by DPP-IV at position 2 (alanine). Substituting this position with aminoisobutyric acid (Aib) in semaglutide confers DPP-IV resistance, extending half-life from 2 minutes to approximately 7 days.

Clinical relevance

Understanding proteolysis is essential for rational peptide drug design. Every decision — route of administration, dosing frequency, chemical modifications — is shaped by the protease environment the peptide will encounter. Subcutaneous injection avoids first-pass hepatic and gastrointestinal proteolysis. Cyclization and D-amino acid substitution extend half-life from minutes to hours or days. PEGylation can extend it further to weeks. The ongoing challenge is achieving protease resistance without sacrificing receptor binding affinity or introducing immunogenicity — a balance that defines the frontier of peptide pharmacology.